- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Longeveron prepares for pivotal HLHS therapy data with FDA meeting | 1 | Investing.com | ||
| Mo | Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) | 94 | GlobeNewswire (Europe) | ELPIS II top-line trial results are anticipated in the third quarter of 2026Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated if ELPIS... ► Artikel lesen | |
| 29.12.25 | Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 | 5 | GlobeNewswire (USA) | ||
| 17.12.25 | Longeveron receives patent for stem cell therapy targeting female sexual dysfunction | 3 | Investing.com | ||
| 17.12.25 | Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy | 1 | GlobeNewswire (USA) | ||
| 03.12.25 | Longeveron executives to speak at CVCT Forum on cell therapy trials | 1 | Investing.com | ||
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| 03.12.25 | Longeveron: Führungskräfte präsentieren auf Fachforum für Zelltherapie-Studien | 1 | Investing.com Deutsch | ||
| 03.12.25 | Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum | 1 | GlobeNewswire (USA) | ||
| 02.12.25 | Longeveron erhält kanadisches Patent für Stammzelltherapie | 1 | Investing.com Deutsch | ||
| 02.12.25 | Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging | 2 | GlobeNewswire (USA) | ||
| 01.12.25 | Longeveron's stem cell therapy shows reduced neuroinflammation in AD trial | 3 | Investing.com | ||
| 19.11.25 | Longeveron stellt Daten zur Alzheimer-Therapie auf der CTAD 2025 vor | 2 | Investing.com Deutsch | ||
| 19.11.25 | Longeveron to present Alzheimer's treatment data at CTAD 2025 | 1 | Investing.com | ||
| 12.11.25 | Longeveron secures patent for stem cell therapy targeting aging frailty | 2 | Investing.com | ||
| 12.11.25 | Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy | 449 | GlobeNewswire (Europe) | The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammagingNo approved... ► Artikel lesen | |
| 12.11.25 | Longeveron: Zwei Vorstandsmitglieder legen Ämter nieder | 4 | Investing.com Deutsch | ||
| 12.11.25 | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.11.25 | Longeveron GAAP EPS of -$0.39 misses by $0.13, revenue of $125M beats by $124.71M | 2 | Seeking Alpha | ||
| 04.11.25 | Longeveron Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 03.11.25 | Earnings Preview For Longeveron | 2 | Benzinga.com |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 44,800 | -2,61 % | CRISPR Therapeutics-Aktie: Wird die Geduld belohnt? | Die Aktie von CRISPR Therapeutics sorgt seit Jahren für starke Volatilität in beide Richtungen und stellt selbst erfahrene Anleger vor Geduldsproben. Zwischen Hoffnungen auf medizinische Durchbrüche... ► Artikel lesen | |
| OCUGEN | 1,360 | +1,23 % | Ocugen closes $22.5 million registered direct offering | ||
| EDITAS MEDICINE | 1,779 | +2,36 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,078 | -1,82 % | Pacific Biosciences stock shows signs of recovery, Canaccord maintains Buy | ||
| CYTODYN | 0,240 | +14,29 % | Ex-CytoDyn CEO sentenced to prison, must pay $5.3M restitution as former CRO leader wins new trial | ||
| DENALI THERAPEUTICS | 17,465 | +0,69 % | Denali, Royalty Pharma Ink $275Mln Royalty Financing Agreement | WASHINGTON (dpa-AFX) - Denali Therapeutics Inc. (DNLI) and Royalty Pharma plc (RPRX) on Thursday announced a $275 million synthetic royalty funding agreement tied to future net sales of Tividenofusp... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,085 | -6,28 % | SOL Global Investments Corp.: SOL Global Announces Settlement of Outstanding Debentures | Toronto, Ontario--(Newsfile Corp. - January 21, 2026) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCD) (FSE: 9SB0) ("SOL" or the "Company") is pleased to announce that it has satisfied its... ► Artikel lesen | |
| TRINITY BIOTECH | 0,902 | -1,43 % | Trinity Biotech plc: Trinity Biotech Announces Agreements to Strengthen Capital Structure and Support Growth Initiatives | - Arrangements provide increased near-term funding and extend maturity of credit agreement to early 2027 - Equity settlement mechanisms also agreed for milestone payments and contingent acquisition... ► Artikel lesen | |
| FATE THERAPEUTICS | 1,091 | +4,91 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates | Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,340 | -0,95 % | Voyager Therapeutics, Inc.: Voyager Reports Third Quarter 2025 Financial and Operating Results | - Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle discovery... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 4,126 | -2,04 % | ANAVEX LIFE SCIENCES CORP kurz vor dem entscheidenden Ausbruch! | ||
| ARCTURUS THERAPEUTICS | 7,430 | +0,81 % | Roth/MKM stuft Arcturus Therapeutics mit "Buy" ein und sieht 163 % Kurspotenzial | ||
| BIOAGE LABS | 16,400 | +6,49 % | BioAge Labs, Inc.: BioAge Announces Pricing of Upsized $115.0 Million Public Offering | EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates... ► Artikel lesen | |
| CERUS | 2,024 | -1,56 % | Cerus Corporation: DRK Blood Donation Service Baden-Württemberg - Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus' INTERCEPT Blood System in Routine Clinical Practice | Cerus Corporation (Nasdaq: CERS) today announced the start of the INITIATE study by the German Red Cross Blood Donation Service Baden-Württemberg Hessen and its subsidiary organization, the German... ► Artikel lesen | |
| LINEAGE CELL THERAPEUTICS | 1,400 | +3,70 % | Regenerative Medizin im Aufschwung: NurExone Biologic, Regenxbio und Lineage Cell Therapeutics setzen auf unterschiedliche Strategien |
LONGEVERON INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -9,24 % bei einem Aktienkurs von 0,564 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LONGEVERON INC finden Sie auf Wallstreet Online.